Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations

Saved in:

Bibliographic Details
Main Authors:	Carlos Jimenez-Vicente, Aina Cardus, Sandra Castaño-Diez, Guillermo Ramil, Sara Garcia-Avila, Lucia Gomez-Perez, Daniel Esteban, Iago Arribas, Antonella Lucia Sturla, Monica Lopez-Guerra, Alexandra Martinez-Roca, Albert Cortes-Bullich, Amanda Isabel Perez-Valencia, Ines Zugasti, Ines Monge, Esther Carcelero, Ferran Vall-Llovera, Susana Vives, Jorge Sierra, Josep Nomdedeu, Guadalupe Oñate, Ana Garrido, Marta Pratcorona, Helena Pomares, Montserrat Arnan, Francesca Guijarro, Marina Diaz-Beya, Jordi Esteve, on behalf of the Spanish CETLAM Group
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-05-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-025-01298-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet